A case series of post-transplant cyclophosphamide in unrelated donor hematopoietic transplantation for aplastic anemia
Abstract
Patients with severe aplastic anemia who fail immunosuppressive therapy have a dismal prognosis. Hematopoietic stem cell transplantation (HSCT) from an unrelated donor (URD) is one of the most effective options. Two institutions have independently adopted a PTCy approach for patients undergoing HSCT from URD. Thirteen patients were included, 11 of which had been treated with immunosuppressive therapy. Most (8/13) had a mismatched URD. All patients were conditioned with fludarabine, cyclophosphamide and TBI in various dose combinations. PTCy was given in a dose of 100 mg/kg. Two patients died, and overall survival was 85% at 2 years. All patients engrafted but one developed secondary graft failure. Overall survival at 2 years was 85%. Of the eleven patients alive after 2 years, nine have complete donor chimerism. All surviving patients are transfusion independent. Ten (77%) patients had CMV reactivation, and two patients had more than one reactivation. No EBV reactivation or PTLD was observed. Four patients had mild hemorrhagic cystitis. In summary, we have shown that the PTCy is a promising approach for aplastic anemia in the URD setting.
How strong is the evidence?
Evidence Hub reads this as a case series, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Drug repositioning: a brief overview
- Cyclic nucleotide phosphodiesterases in Drosophila melanogaster
- Time-resolved in silico modeling of fine-tuned cAMP signaling in platelets: feedback loops, titrated phosphorylations and pharmacological modulation
- Current View on Green Tea Catechins Formulations, Their Interactions with Selected Drugs, and Prospective Applications for Various Health Conditions
- In silico Structure-based Identification of Novel Acetylcholinesterase Inhibitors Against Alzheimer’s Disease
- Development and In Vitro Evaluation of Controlled Release Viagra® Containing Poloxamer-188 Using Gastroplus™ PBPK Modeling Software for In Vivo Predictions and Pharmacokinetic Assessments
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.